摘要
目的探讨联合使用脂康颗粒和阿托伐他汀治疗高脂血症的疗效及安全性。方法将80例高脂血症患者按照就诊先后顺序随机分为对照组和治疗组各40例,对照组给予阿托伐他汀20mg,每日1次口服;治疗组在服用阿托伐他汀的基础上加服脂康颗粒,每次8.0g(1袋),每日2次冲服。疗程均为8周,并于治疗前、治疗后第4周、治疗后第8周,检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)的变化,同时监测血常规、尿常规、肝肾功能及药物不良反应。结果治疗结束,治疗组总有效率在治疗第4周(97.5%,39/40)、第8周(100%,40/40)均高于对照组(P<0.05);其中治疗组4周后临床控制率达40.0%(16/40)高于对照组的17.5%(7/40),治疗8周后临床控制率达到52.5%(21/40)高于对照组的27.5%(11/40)(P<0.05)。两组治疗后TC、TG、LDL-C与治疗前比较均明显下降,HDL-C则明显上升(P<0.05)。治疗组治疗4周、8周后与对照组比较TC、TG、LDL-C亦有明显下降,而HDL-C则明显升高(P<0.05)。两组患者治疗后与治疗前比较各种自觉不适症状均有明显的改善,其中治疗组在治疗8周后与对照组比较头胀、耳鸣眼花、腰膝酸软、胸闷胸痛等症状的发生有显著下降(P<0.05)。治疗后4周、8周复查血常规、尿常规、肝功能、肾功能相关指标,除对照组出现血清转氨酶轻度升高外(正常上限3倍以内),其余指标均未出现异常。结论降脂中成药脂康颗粒联合阿托伐他汀能有效调节血脂异常,治疗高脂血症总体疗效好于单用阿托伐他汀,且较单纯使用阿托伐他汀安全性高,值得临床推广使用。
Objective To evaluate the efficacy and safety of combined use of Zhikang granule （ZKG） and atorvastatin in the treatment of hyperlipidemia. Methods Eighty out-patients with hyperlipemia who met the inclusion criteria were enrolled and randomly divided into two groups： treatment group （ZKG-atorvastatin, n = 40） and control group （atorvastatin alone, n ~ 40）. Patients in both groups received oral administration of atorvastatin 20 mg once daily, while patients in the treatment group also took ZKG 8 g after mixing with water twice daily. The treatment course was eight weeks. Serum total cholesterol （TC）, triglyceride （TG）, high density lipoprotein cholesferol （HDL- C） and low density lipoprotein cholesterol （LDL-C） were determined before the treatment, 4 and 8 weeks after the treatment. Routine blood and urine examination, liver and kidney function and adverse drug reactions of the patients were also monitored. Results The total response rates at 4 and 8 weeks after the treatment showed increase trend in the treatment group as compared with those in the control group（ P 〈0.05）. The clinical control rates at 4 and 8 weeks after the treatment were 40.0% （16/40） and 52.5 % （21/40） in the treatment group, significantly higher than those in the control group, respectively （17.5% ,7/40 and 27.50/oo ,11/40, P 〈0.05）. After the treatment, the levels of TC, TG and LDL-C in both groups decreased significantly, but HDL-C increased markedly as compared with those before the treatment （ P 〈0.05）. A variety of discomfort symptoms were improved obviously in both groups after the treatment. At 8 weeks after the treatment, the incidence of tinnitus, vertigo, headache and ch^eSt tightness/pain in the treatment group decreased markedly as compared with those in the control group （P 〈0.05）. No significant side effect was observed during the treatment except one case in the control group having mild elevation of serum transaminase. Conclusion ZKG combined with atorvastatin is
出处
《临床荟萃》
CAS
2015年第3期268-272,共5页
Clinical Focus
